7DC Stock Chart & Stats
€1.77
€0.11(7.01%)
At close: 4:00 PM EST
€1.77
€0.11(7.01%)
Day’s Range― - ―
52-Week Range€1.39 - €2.04
Previous CloseN/A
Volume2.58K
Average Volume (3M)97.00
Market Cap
€127.69M
Enterprise Value€102.17
Total Cash (Recent Filing)€7.34M
Total Debt (Recent Filing)€1.15M
Price to Earnings (P/E)1172.7
Beta0.52
Next Earnings
Sep 29, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding84,922,280
10 Day Avg. Volume134
30 Day Avg. Volume97
Financial Highlights & Ratios
PEG Ratio-11.04
Price to Book (P/B)2.67
Price to Sales (P/S)2.82
P/FCF Ratio75.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.53Price Target Upside42.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€535.71K
Bulls Say, Bears Say
Bulls Say
New ContractsDiaceutics has successfully renegotiated its first PMx contract with the new commercial licensee, which is worth £4.5m in recurring service revenues.
Revenue GrowthAnother year of strong organic revenue growth in FY24 (+36% to £32.2m) and continued momentum into the first four months of 2025 (+35% to £8.4m), puts the business well on track to deliver on current revenue (+25%) and EBITDA expectations for FY25.
Strategic PartnershipsDiaceutics now works with 18 of the top 20 global pharma companies across 56 therapeutic brands, highlighting significant customer and brand wins.
Bears Say
Order Book DeclineThe year-end order book was down 11% to £24.9m compared to the previous year, and recurring revenues were broadly flat at 55%.
Diaceutics News
7DC FAQ
What was Diaceutics’s price range in the past 12 months?
Diaceutics lowest stock price was €1.39 and its highest was €2.04 in the past 12 months.
What is Diaceutics’s market cap?
Diaceutics’s market cap is €127.69M.
When is Diaceutics’s upcoming earnings report date?
Diaceutics’s upcoming earnings report date is Sep 29, 2026 which is in 66 days.
How were Diaceutics’s earnings last quarter?
Diaceutics released its earnings results on May 26, 2026. The company reported €0.035 earnings per share for the quarter, the consensus estimate of €0.035 by €0.
Is Diaceutics overvalued?
According to Wall Street analysts Diaceutics’s price is currently Undervalued.
Does Diaceutics pay dividends?
Diaceutics does not currently pay dividends.
What is Diaceutics’s EPS estimate?
Diaceutics’s EPS estimate is -0.04.
How many shares outstanding does Diaceutics have?
Diaceutics has 84,922,280 shares outstanding.
What happened to Diaceutics’s price movement after its last earnings report?
Diaceutics reported an EPS of €0.035 in its last earnings report, expectations of €0.035. Following the earnings report the stock price went down -1.129%.
Which hedge fund is a major shareholder of Diaceutics?
Currently, no hedge funds are holding shares in DE:7DC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Diaceutics
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and implementation support. Central to its operations is the DXRX platform. This platform features DXRX data solutions, providing access to extensive diagnostic testing data pipelines from a broad network of laboratories, including real-time DXRX signal alerts, lab and physician mapping, and a testing dashboard. The DXRX platform also hosts a marketplace where laboratories, pharmaceutical firms, and diagnostic companies can connect to collaborate on precision medicine diagnostics. Diaceutics further provides DXRX Patient Journey, a tool for pharmaceutical clients to conduct detailed longitudinal analyses of individual patient biomarker testing paths, helping identify opportunities for earlier intervention and treatment. DXRX Lab Benchmarking allows laboratories to sharpen their competitive edge by comparing their key criteria against industry counterparts, encompassing metrics such as disease focus, testing methodologies, market share, turnaround times, and their standing as leaders in specific diagnostic fields. The DXRX Test Reimbursement service assists pharma clients in funding novel companion diagnostics, thereby shortening the time required for their widespread adoption. Furthermore, DXRX Test Signal delivers immediate notifications of testing events, empowering pharmaceutical clients to swiftly identify therapeutically actionable patients. Beyond the platform, Diaceutics furnishes services for diagnostic landscape analysis, strategic planning, implementation, and ongoing tracking, alongside expert consulting tailored to precision medicine diagnostics. Its extensive service portfolio also covers test standardization, quality evaluations, optimization of test reports, technical laboratory support, assistance with test access and reimbursement, laboratory training, and various educational resources.
7DC Stock 12 Month Forecast
Average Price Target
€2.53
▲(42.78% Upside)